Icosavax Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023 16:05 ET
|
Icosavax, Inc.
- IVX-A12 (RSV+hMPV) Phase 1 topline interim data expected in 2Q 2023 - - Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 - - Cash and cash equivalents, restricted cash, and short-term...
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K
April 26, 2023 12:15 ET
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, announced today that it received a notice...
Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 30, 2023 16:05 ET
|
Icosavax, Inc.
- FDA granted Fast Track Designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine candidate - - Completed dosing in ongoing Phase 1 study of...
New Technology Can Now Test for Airborne COVID and Several Strains of the Common Flu
March 01, 2023 23:35 ET
|
AirAnswers Inc
NORTH CHICAGO, Ill., March 01, 2023 (GLOBE NEWSWIRE) -- AirAnswers, the leader in air sampling and testing technology, is expanding their test offering to include a panel of airborne viruses...
Icosavax to Participate in the Upcoming Healthcare Conferences
February 28, 2023 08:00 ET
|
Icosavax, Inc.
SEATTLE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Granted FDA Fast Track Designation for IVX-A12
February 21, 2023 08:00 ET
|
Icosavax, Inc.
SEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Provides Corporate Update and Anticipated Milestones for 2023
January 06, 2023 08:00 ET
|
Icosavax, Inc.
- Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of potential differentiation on durability with company’s VLP platform - - Phase 1 study of...
Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
December 14, 2022 08:30 ET
|
Dyadic International, Inc.
“Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge” Study supports: Dyadic’s...
爱科百发宣布呼吸道合胞病毒新药爱司韦®的上市许可申请获国家药品监督管理局正式受理并纳入优先审评审批程序
December 08, 2022 20:00 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
中国上海, Dec. 09, 2022 (GLOBE NEWSWIRE) -- 上海爱科百发生物医药技术股份有限公司（以下简称“ 爱科百发”），一家致力于儿科及呼吸疾病领域创新药研发的生物制药企业，今日宣布中国国家药品监督管理局正式受理治疗呼吸道合胞病毒（RSV）感染新药爱司韦®（通用名：齐瑞索韦/ziresovir）的上市许可申请（NDA），并且纳入“优先审评审批”程序。 ...
Ark Biopharmaceutical Announces NMPA Acceptance and Priority Review of New Drug Application for Ziresovir for Treatment of RSV Infection
December 08, 2022 20:00 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
SHANGHAI, China, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Shanghai Ark Biopharmaceutical Co., Ltd. (Ark Biopharmaceutical), a biopharma company dedicated to the discovery and development of drugs for...